PYC Therapeutics Opens Retail Component of Entitlement Offer to Fund RNA Therapy Pipeline

PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an announcement.

PYC Therapeutics has opened the retail component of its previously announced 3-for-5 pro rata accelerated non-renounceable entitlement offer, giving eligible retail shareholders in Australia and New Zealand the opportunity to participate. The Retail Entitlement Offer opens on 9 February 2026 and is scheduled to close at 5:00 p.m. AEDT on 27 February 2026, with documentation and participation instructions being dispatched electronically or by letter to eligible investors.

The move underscores PYC’s ongoing capital-raising efforts to support its RNA therapeutic pipeline and could broaden its retail investor base while reinforcing shareholder participation in the company’s funding strategy. Eligible retail investors are urged to review the retail offer materials carefully and seek professional advice before deciding whether to take up their entitlements, highlighting the importance of informed decision-making amid continued development of PYC’s monogenic disease programs.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on creating a new generation of RNA therapies for patients with genetic diseases. The company leverages a proprietary drug delivery platform to boost the potency of precision medicines within the rapidly expanding RNA therapeutics class, with development programs targeting monogenic diseases that have a relatively high likelihood of clinical success.

Average Trading Volume: 686,170

Technical Sentiment Signal: Buy

Current Market Cap: A$1.4B

See more insights into PYC stock on TipRanks’ Stock Analysis page.